Renalys Overview

  • Year Founded
  • 2023

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

Renalys General Information

Description

Developer of a therapeutic platform designed to revolutionize renal disease management for Asian patients. The company's platform integrates a first-in-class, oral Dual Endothelin Angiotensin Receptor Antagonist, effectively suppressing IgA Nephropathy progression by inhibiting crucial pathways, Endothelin-1 and Angiotensin II, enabling healthcare professionals with a viable alternative to current inadequate treatments and offering a significant leap forward in renal care.

Contact Information

Website
www.renalys.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 3-11, Nihonbashi-honcho2-chome
  • Chuo-ku
  • Tokyo, 103-0023
  • Japan
Primary Industry
Drug Discovery
Acquirer
Chugai Pharmaceutical
Vertical(s)
HealthTech, Life Sciences
Corporate Office
  • 3-11, Nihonbashi-honcho2-chome
  • Chuo-ku
  • Tokyo, 103-0023
  • Japan

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Renalys Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Merger/Acquisition 01-Nov-2025 Completed Clinical Trials - Phase 3
2. Early Stage VC (Series A) 17-Jul-2024 Completed Clinical Trials - Phase 3
1. Seed Round 11-Jan-2024 Completed Clinical Trials - Phase 3
To view Renalys’s complete valuation and funding history, request access »

Renalys Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Class A Preferred Shares
To view Renalys’s complete cap table history, request access »

Renalys Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a therapeutic platform designed to revolutionize renal disease management for Asian patients. The company's
Drug Discovery
Tokyo, Japan

Stockholm, Sweden
 

San Diego, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Renalys Competitors (2)

One of Renalys’s 2 competitors is Calliditas Therapeutics, a Formerly VC-backed company based in Stockholm, Sweden.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Calliditas Therapeutics Formerly VC-backed Stockholm, Sweden
Travere Therapeutics Formerly VC-backed San Diego, CA
You’re viewing 2 of 2 competitors. Get the full list »

Renalys Former Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
Catalys Pacific Venture Capital Minority
Japan Post Bank Asset Management PE/Buyout Minority
Nippon Venture Capital Corporate Venture Capital Minority
SR One Corporate Venture Capital Minority
Sumitomo Mitsui Trust Group Holding Company Minority
You’re viewing 5 of 6 investors. Get the full list »

Ready to get started?

Request a free trial

Renalys FAQs

  • When was Renalys founded?

    Renalys was founded in 2023.

  • Where is Renalys headquartered?

    Renalys is headquartered in Tokyo, Japan.

  • What industry is Renalys in?

    Renalys’s primary industry is Drug Discovery.

  • Is Renalys a private or public company?

    Renalys is a Private company.

  • What is Renalys’s current revenue?

    The current revenue for Renalys is .

  • How much funding has Renalys raised over time?

    Renalys has raised $37.6M.

  • Who are Renalys’s investors?

    Catalys Pacific, Japan Post Bank Asset Management, Nippon Venture Capital, SR One, and Sumitomo Mitsui Trust Group are 5 of 6 investors who have invested in Renalys.

  • Who are Renalys’s competitors?

    Calliditas Therapeutics and Travere Therapeutics are competitors of Renalys.

  • When was Renalys acquired?

    Renalys was acquired on 01-Nov-2025.

  • Who acquired Renalys?

    Renalys was acquired by Chugai Pharmaceutical.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process